Head of Strategic Pharma Partnerships, Oncology

Join a team of brilliant, passionate innovators determined to transform healthcare. At BillionToOne, we've built a category-defining, publicly traded company on Nasdaq where transparency fuels trust, collaboration drives breakthroughs, and every contribution moves the needle on our mission to make life-changing diagnostics accessible to all. We don't just aim for incremental improvements; we build products that are 10x better than anything that exists today.

Our scientists, engineers, sales executives, and visionaries are united by an unwavering commitment to changing the standard of care in prenatal and cancer diagnostics. This is where cutting-edge science meets human compassion, and every innovation you contribute helps remove the fear of the unknown from some of life's most critical medical moments.

If you're driven by purpose, energized by innovation, and ready to help shape the future of precision medicine at scale, this is where you belong.

We are seeking an entrepreneurial and highly strategic leader for the Head of Strategic Pharma Partnerships, Oncology role. This position is pivotal in driving BillionToOne’s growth by forging impactful partnerships with pharmaceutical companies and exploring innovative product opportunities in the precision diagnostics and oncology space. The role combines business development expertise with product exploration to identify and validate new use cases for our oncology liquid biopsy solutions.

The ideal candidate will have a strong understanding of both the technical and commercial aspects of precision diagnostics, excel in customer engagement, and thrive in a fast-paced, dynamic environment. This role reports to the Chief Product Officer.

• →Actively identify and engage pharmaceutical companies to build strategic partnerships for BillionToOne’s oncology product lines.
• →Negotiate and close partnership agreements that drive business growth and align with our strategic goals.
• →Represent BillionToOne at industry conferences and events to establish and strengthen relationships with key stakeholders.
• →Collaborate with internal teams (R&D, Clinical, and AI) to identify new product opportunities and validate their potential with pharmaceutical partners.
• →Act as the primary advocate for pharmaceutical customers, deeply understanding their needs and translating them into actionable product insights.
• →Partner with internal teams to co-develop solutions that address unmet needs in oncology diagnostics.
• →Work with Clinical and R&D teams to align on technical feasibility and ensure smooth execution of partnership projects.
• →Collaborate with legal and finance teams to structure and finalize deal terms.
• →Maintain a feedback loop with internal stakeholders to iterate on product concepts and improve partnership success rates.

• 10+ years of experience in business development, product partnerships, or a related role in precision diagnostics or life sciences.
• Proven track record of closing complex deals with pharmaceutical companies.
• Strong understanding of oncology diagnostics and liquid biopsy technologies.
• Ability to bridge the gap between technical teams and business stakeholders, translating scientific concepts into commercial opportunities.
• Exceptional communication and relationship-building skills.
• Entrepreneurial mindset with a passion for product innovation and customer success.
• Strategic thinker with the ability to execute effectively in a dynamic, fast-paced environment.
• Willingness to travel (up to 25%) to engage partners and attend key industry events.

Unity Complete™ is the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Our Northstar® liquid biopsy test uniquely combines treatment selection with real-time monitoring, giving oncologists unprecedented precision in cancer care.

From $0 to $150M+ in Annual Recurring Revenue in just five years. In 2025, we completed one of the most successful IPOs for a medical diagnostics company, building on nearly $400M in private funding,including our $130M Series D in 2024 and backed by world-class investors including Hummingbird, Adams Street Partners, Neuberger Berman, Baillie Gifford, and Premji Invest.

Forbes named us one of America's Best Startup Employers for 2025 and we're Great Place to Work certified, with 100% of our people willing to go the extra mile, even as we've scaled to over 700 employees.

Headquartered in Menlo Park with facilities in Union City, CA, and a new lab opening in Austin, TX in 2027, we're continuing to push the boundaries of what's possible in molecular diagnostics. We're just getting started.

Ready to help us change the world, one molecule at a time? Learn more at billiontoone.com